lymphocytes

[BMC Immunology] Scientists examined the expression of NKG2DLs, PD-L1 and PD-L2 in lung cancer cells after treatment of TGF-β and a TGF-β inhibitor, Galunisertib.

[Clinical Cancer Research] Scientists examined the effects of a rapamycin pretreatment of epithelial cell adhesion molecule (EpCAM) chimeric antigen receptor (CAR)-T cells and assessed the in vivo antitumor efficacy of rapamycin pretreated EpCAM CAR-T cells and CD33 CAR-T cells in leukemia xenograft mouse models.

[INmune Bio, Inc.] INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.

[LAVA Therapeutics, N.V.] LAVA Therapeutics N.V. announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

[Blood Cancer Journal] Investigators compared long-term outcomes of 106 patients having T cell mixed chimerism after day 60 and undergoing allogeneic stem cell allograft for acute leukemia from an unrelated donor, with 111 patients having complete chimerism.

[Blood] The authors performed single-cell transcriptome analysis of residual hematopoietic stem and progenitor cells and T cells to identify the molecular players from patients with aplastic anemia.